Figure 2.

ACML-55 enhances tumor surveillance. A: ACML-55 treatment delays CT26 melanoma tumor formation. Sex- and age-matched BALB/c mice were administered orally either with 2 mg/mL (200 μL/mouse) ACML-55 or equivalent volume of PBS (control) daily for fifteen days (n = 20 for each group), followed by subcutaneous inoculation of CT26 melanoma tumor cells (5 × 10⁵/mouse) on day 7 after the initiation of ACML-55 or PBS treatment. Tumor growth was recorded daily. Tumor size > 5 mm × 5 mm was considered positive. Data represents three independent experiments (P < 0.01). B: ACML-55 treatment inhibits tumor growth. The mean tumor size from ACML-55 and PBS-treated mice at day 20 is shown in this figure (P < 0.01). C: ACML-55 treatment significantly reduces intraperitoneal tumor formation. BALB/c mice were treated with ACML-55 or PBS followed by CT26 tumor cell inoculation intraperitoneally (n = 20 for each group) as described above, and tumor growth was monitored. A representative example of tumor formation is provided. Arrows point to intraperitoneal tumor.